Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
The Global Generics and Biosimilars Awards celebrate the greatest achievements and innovations across the development, authorisation, marketing and distribution of global off-patent pharmaceuticals. Co-locating with CPhI Worldwide in Frankfurt, these illustrious awards provide a unique opportunity for the industry to come together to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change. Winners will be recognised across 14 categories, including Biosimilar Initiative of the Year, Leader of the Year, API Supplier of the Year and Business Development of the Year.
The Global Generics and Biosimilars Awards are free to enter. The closing date for entries is 19 August 2022, and the qualifying period for submissions is 1 July 2021 - 31 July 2022. The judging process will take place over the summer. The finalists will be announced in September and the winners revealed at the Awards on 2 November 2022.
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business. There are awards for the following regions: Americas / EMEA / Asia-Pacific.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or Intermediates.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
This category allows generics, biosimilars and value-added medicines firms as well as their partnering law firms to highlight outstanding results from their approach to intellectual property and their legal strategy. This could include notable litigation results allowing a competitive advantage or early launch; inventive ways of getting around or invalidating intellectual property; obtaining intellectual property to protect their own products or processes; or ways in which legal strategies or IP approaches from different global jurisdictions have been used as a template elsewhere, showing the benefits of a coordinated international IP strategy.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Awarded to recognise outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract manufacturers, law firms and consultants.
Evidence cited in supporting text could include: market data to show commercial success; details of deals done, synergies delivered, and integration goals achieved; brief accounts of litigation and other legal action; or responses and testimonials from customers. Please note: the activities in question should have taken place between 1 July 2021 - 31 July 2022.
These awards are open to any company or individual involved in developing, authorizing, marketing and distributing generics or biosimilars. The qualifying period for submissions is 1 July 2021 - 31 July 2022.
Aurelio Arias
Aaron Barkoff
Stuart Colligon
Frances Cloud
Duncan Emerton
Chloe Kent
Suzette Kox
Ewan Livesey
Doug Long
Axel Muller
Julie Reed
Dean Rudge
Maja Sercic
Alan Sheppard
Christine Simmon
Eva Temkin
Adrian Van Der Hoven
James Vane Tempest
David Wallace
Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis. Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.Prior to IQVIA, Aurelio has worked in R&D and in various strategy consulting roles. He holds an MSci in Chemistry from Imperial College London.
Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020). Ewan currently works as a consultant to several companies and PE firms advising on corporate strategy including all elements of business development from acquisition to licensing and portfolio selection.
Doug Long is Vice President of Industry Relations at IQVIA (formerly QuintilesIMS) one the world’s largest pharmaceutical information company. IQVIA offers services to the pharmaceutical industry in over 101 countries around the globe. Doug has been with IQVIA since 1989. His fundamental task is to help secure data for all existing and new databases supported by IQVIA, manage supplier, manufacturer & association relationships, and develop information for data partners. As direct consequence of his involvement in these areas, Doug has considerable experience with, and a unique perspective on, the changing U.S. and global healthcare marketplace and pharmaceutical distribution.
By education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013. Since 2014 Axel is working as Consultant – mainly but not only in the Pharmaceutical Industry. After some years working as Senior Advisor of Arthur D. Little he joined 2018 Fidelio Healthcare Partners as Associated Partner. In addition, Axel is non-executive member of several supervisory and advisory boards.
Juliana (Julie) Reed currently serves as the Executive Director of the Biosimilars Forum, leading strategy for the group’s strategic efforts to increase access to and adoption of biosimilars. Reed served as the Forum’s President for more than eight years and was one of its founders. As the Biosimilars Forum President, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States. She brings more than 30 years of experience in the healthcare sector to the Forum. Most recently, Reed was Vice President and Global Corporate Affairs Lead with Pfizer, specializing in immunology, inflammation and biosimilars portfolios. She also has experience in executive roles leading global corporate and government affairs for Hospira and Coherus BioSciences.
Maja Sercic is a Policy & Science Manager at Medicines for Europe and coordinator of Value Added medicines sector group. Maja is pharmacists by training. Before joining Medicines for Europe, she worked in the pharmaceutical industry, working on the off-patent development projects liaising with the external partners across the industry. Medicines for Europe represents the pharmaceutical companies supplying the largest share of medicines across Europe and is the voice of the generic, biosimilar and value-added industries. As a leading partner for better healthcare aims to increase the health and wellbeing of all Europeans through better access to high-quality medicines.
Christine Simmon joined the Association for Accessible Medicines (AAM) in 2012 and is the Executive Vice President, Policy and Strategic Alliances. Christine also serves as Executive Director of the Biosimilars Council, the AAM subsidiary that advocates for greater access for patients to biosimilar medicines. In her current role, Christine is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups. Christine had previously served as Vice President of Policy, Public Affairs & Development at AAM from 2002 to 2006 and Senior Vice President of Policy & Strategic Alliances from 2012 to 2021. Before rejoining the association, she was the Senior Director of Public Policy for CVS Caremark, where she was the policy lead for the integrated retail, convenient care clinic and pharmacy benefit manager enterprise at both the state and federal levels. Previously, Christine was a Senior Policy Analyst at BlueCross BlueShield Association, where she helped position the insurer as a leading voice on pharmaceutical cost and safety issues. Christine received her J.D. from Georgetown University Law Center and her B.A. in American Studies from Georgetown University.
Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.
Ready to submit your entry to the Global Generics & Biosimilars Awards 2022? Enter today to be in with a chance of winning
Enter Now
Sponsorship of the Global Generics & Biosimilars Awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.
Sponsor Opportunities
IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.
The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
Pharmawise is a specialist pharmaceutical consultancy. We give our clients strategic, commercial and scientific advice and support through our international network of industry experts. With deep expertise in your sector, we can help you tackle your most complex and specialised challenges; develop your strategic and operational plans; and improve the efficiency of your operations.
SanaClis was founded in 2000 by seasoned industry experts all of whom have had executive level positions in leading pharma companies and large global CROs. SanaClis is a full-service European CRO offering a comprehensive range of services for clinical trials.
SanaClis has experience of successfully delivering studies for various sized sponsors, starting from virtual biotechs through to top 10 pharma companies. Every project is a priority for the SanaClis team, irrespective size or scope. We believe that every company and professional deserves to feel that they are getting the best possible service, responsiveness and dedication that we routinely provide to our existing clients.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
